3-(1-Hydroxy-2-piperidinoethyl)-5-phenylisoxazole citrate | 2139-25-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 3-(1-Hydroxy-2-piperidinoethyl)-5-phenylisoxazole citrate
• 英文别名: 2-hydroxypropane-1,2,3-tricarboxylic acid;1-(5-phenyl-1,2-oxazol-3-yl)-2-piperidin-1-ylethanol
• CAS: 2139-25-5
• 化学式: C22H28N2O9
• 分子量: 464.5
• InChiKey: LLIFHVXJAXBPMC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.61
• 重原子数：
  33
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  182
• 氢给体数：
  5
• 氢受体数：
  11

文献信息

• Novel pharmaceutical compounds
  申请人：Grimm Erich L.

  公开号：US20080188521A1

  公开（公告）日：2008-08-07

  The instant invention provides compounds of Formula I which are leukotriene biosynthesis inhibitors. Compounds of Formula I are useful as anti-atherosclerotic, anti-asthmatic, anti-allergic, anti-inflammatory and cytoprotective agents.

  这种瞬间发明提供了化合物I的公式，这些化合物是白三烯生物合成抑制剂。 公式I的化合物可用作抗动脉粥样硬化、抗哮喘、抗过敏、抗炎和细胞保护剂。
• [EN] 7- (1, 3-THIAZOL-2-YL)THIO!-COUMARIN DERIVATIVES AND THEIR USE AS LEUKOTRIENE BIOSYNTHESIS INHIBITORS<br/>[FR] DERIVES DE 7- (1,3-THIAZOL-2-YL)THIO !COUMARINE ET UTILISATION DE CEUX-CI EN TANT QU'INHIBITEURS DE LA BIOSYNTHESE DES LEUCOTRIENES
  申请人：MERCK FROSST CANADA INC

  公开号：WO2004108720A1

  公开（公告）日：2004-12-16

  The instant invention provides compounds of Formula (I) which are leukotriene biosynthesis inhibitors. Compounds of formula (I) are useful as anti-asthmatic, anti-allergic, anti-inflammatory, cytoprotective and anti-artherosclerotic agents.

  这种瞬时发明提供了化合物的公式(I)，这些化合物是白三烯生物合成抑制剂。公式(I)的化合物可用作抗哮喘、抗过敏、抗炎、细胞保护和抗动脉粥样硬化药物。
• [EN] 5-OXO-ETE RECEPTOR ANTAGONIST COMPOUNDS<br/>[FR] COMPOSÉS ANTAGONISTES DES RÉCEPTEURS 5-OXO-ETE
  申请人：UNIV MCGILL

  公开号：WO2010127452A1

  公开（公告）日：2010-11-11

  The present invention relates to novel pharmaceutically-useful compounds which are antagonists of the 5-oxo-ETE receptors, such as the OXE receptor. These compounds have use as therapeutic and/or prophylactic agents for diseases characterized by tissue eosinophilia, such as inflammatory conditions including respiratory diseases. The invention also relates to pharmaceutical compositions, to the use of such compounds and compositions as medicaments, and to therapeutic methods.

  本发明涉及一种新型的药用化合物，它们是5-oxo-ETE受体的拮抗剂，如OXE受体。这些化合物可用作治疗和/或预防组织嗜麻细胞增多等疾病的药物，如包括呼吸道疾病在内的炎症性疾病。该发明还涉及制药组合物，以及将这些化合物和组合物用作药物、以及治疗方法。
• Percutaneous absorption-type pharmaceutical preparation
  申请人：Inosaka Keigo

  公开号：US20060275354A1

  公开（公告）日：2006-12-07

  A stable percutaneous absorption-type pharmaceutical preparation for percutaneous administration of drugs except for selegiline and selegiline hydrochloride, which does not suffer a decrease in the cohesive force of the adhesive layer therein even in the presence of sweat components due to perspiration during wear and which is free from cohesive failure and resultant adhesive remaining when stripped off. A percutaneous absorption-type pharmaceutical preparation which comprises: a support; and an adhesive layer containing an adhesive, a metal chloride and a percutaneously-absorptive drug except for selegiline and selegiline hydrochloride, wherein the adhesive layer is subjected to a crosslinking treatment.

  一种稳定的经皮吸收型药物制剂，用于除去赛洛吉林和赛洛吉林盐酸盐以外的药物的经皮给药，即使在穿戴过程中由于出汗而存在汗液成分时也不会减少粘合层的粘合力，并且在剥离时不会出现内聚力失效和残留粘合剂。一种经皮吸收型药物制剂，包括：一种支撑物；和一个含有粘合剂、金属氯化物和除赛洛吉林和赛洛吉林盐酸盐之外的经皮吸收药物的粘合层，其中粘合层经过交联处理。
• Suppository and composition comprising at least one polyethylene glycol
  申请人：Anestic ApS

  公开号：US20020048601A1

  公开（公告）日：2002-04-25

  There is provided a suppository comprising at least one biocompatible polymer, wherein the biocompatible polymer is essentially non-biodegradable, and wherein the suppository essentially does not swell when contacted with an aqueous fluid. The suppository may further comprise a plurality of open cells at least partly separated from one another by an interpenetrating matrix comprising at least one biocompatible polymer in branched or crosslinked form. The plurality of interlinked, open cells are capable of containing an aqueous fluid, and the permeability of the suppository ensures that entry of body fluids into the open cells under practical circumstances occurs essentially without dehydration of mucousal membrane tissue contacting the suppository. The suppository furthermore preferably comprises a controlled release formulation.

  提供了一种含有至少一种生物相容性聚合物的栓剂，其中该生物相容性聚合物基本上不可生物降解，且当与水性液体接触时，该栓剂基本上不膨胀。该栓剂还可以进一步包括多个开放单元，这些单元至少部分地由相互穿插的基质分隔开，该基质包含至少一种分支或交联形式的生物相容性聚合物。这些互相连接的开放单元能够包含水性液体，而栓剂的渗透性确保体液进入开放单元时，在实际情况下基本上不会导致接触栓剂的粘膜组织脱水。此外，该栓剂最好包含控制释放配方。